Cargando…
Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016
OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumo...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404672/ https://www.ncbi.nlm.nih.gov/pubmed/30881060 http://dx.doi.org/10.2147/IDR.S193638 |
_version_ | 1783400938318331904 |
---|---|
author | Liao, Chun-Hsing Lee, Na-Yao Tang, Hung-Jen Lee, Susan Shin-Jung Lin, Chin-Fu Lu, Po-Liang Wu, Jiunn-Jong Ko, Wen-Chien Lee, Wen-Sen Hsueh, Po-Ren |
author_facet | Liao, Chun-Hsing Lee, Na-Yao Tang, Hung-Jen Lee, Susan Shin-Jung Lin, Chin-Fu Lu, Po-Liang Wu, Jiunn-Jong Ko, Wen-Chien Lee, Wen-Sen Hsueh, Po-Ren |
author_sort | Liao, Chun-Hsing |
collection | PubMed |
description | OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla(KPC), bla(NDM), bla(IMP), bla(VIM), and bla(OXA-48-like)) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1–5) was conducted for all isolates with colistin MICs ≥4 mg/L. RESULTS: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime–avibactam (CAZ–AVB), and ceftolozane–tazobactam (CLZ–TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring bla(KPC) and one harboring bla(OXA-48-like)), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcr genes. CONCLUSION: CAZ–AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ–TAZ exhibited good activity against imipenem-resistant P. aeruginosa. |
format | Online Article Text |
id | pubmed-6404672 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-64046722019-03-16 Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 Liao, Chun-Hsing Lee, Na-Yao Tang, Hung-Jen Lee, Susan Shin-Jung Lin, Chin-Fu Lu, Po-Liang Wu, Jiunn-Jong Ko, Wen-Chien Lee, Wen-Sen Hsueh, Po-Ren Infect Drug Resist Original Research OBJECTIVE: The aim of this study was to investigate the in vitro antimicrobial susceptibilities of clinically important Gram-negative bacteria from seven intensive care units in Taiwan in 2016. MATERIALS AND METHODS: In total, 300 non-duplicate isolates of Escherichia coli (n=100), Klebsiella pneumoniae (n=100), and Pseudomonas aeruginosa (n=100) collected from 300 patients were studied. The minimum inhibitory concentrations (MICs) of these isolates to antimicrobial agents were determined using the broth microdilution method. Carbapenemase-encoding genes (bla(KPC), bla(NDM), bla(IMP), bla(VIM), and bla(OXA-48-like)) were studied for the isolates that were not susceptible to any carbapenems. Sequencing analysis of the mcr genes (mcr-1–5) was conducted for all isolates with colistin MICs ≥4 mg/L. RESULTS: Ertapenem non-susceptibility was detected in 3% (n=3) E. coli and 12% (n=12) K. pneumoniae isolates. The susceptibility rates of imipenem, ceftazidime–avibactam (CAZ–AVB), and ceftolozane–tazobactam (CLZ–TAZ) were 99%, 99%, and 88%, respectively, for E. coli, 91%, 100%, and 80%, respectively, for K. pneumoniae, and 66%, 91%, and 93%, respectively, for P. aeruginosa. Carbapenemase-encoding genes were not detected in E. coli, were detected in four (33.3%) K. pneumoniae isolates that were not susceptible to ertapenem (three harboring bla(KPC) and one harboring bla(OXA-48-like)), and were not detected in P. aeruginosa isolates that were not susceptible to imipenem. One K. pneumoniae isolate was resistant to colistin (MIC 4 mg/L) and negative for mcr genes. CONCLUSION: CAZ–AVB exhibited excellent activity against carbapenem-resistant Enterobacteriaceae, and CLZ–TAZ exhibited good activity against imipenem-resistant P. aeruginosa. SAGE Publications 2019-03-04 /pmc/articles/PMC6404672/ /pubmed/30881060 http://dx.doi.org/10.2147/IDR.S193638 Text en © 2019 Liao et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Liao, Chun-Hsing Lee, Na-Yao Tang, Hung-Jen Lee, Susan Shin-Jung Lin, Chin-Fu Lu, Po-Liang Wu, Jiunn-Jong Ko, Wen-Chien Lee, Wen-Sen Hsueh, Po-Ren Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title | Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title_full | Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title_fullStr | Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title_full_unstemmed | Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title_short | Antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016 |
title_sort | antimicrobial activities of ceftazidime–avibactam, ceftolozane–tazobactam, and other agents against escherichia coli, klebsiella pneumoniae, and pseudomonas aeruginosa isolated from intensive care units in taiwan: results from the surveillance of multicenter antimicrobial resistance in taiwan in 2016 |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404672/ https://www.ncbi.nlm.nih.gov/pubmed/30881060 http://dx.doi.org/10.2147/IDR.S193638 |
work_keys_str_mv | AT liaochunhsing antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT leenayao antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT tanghungjen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT leesusanshinjung antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT linchinfu antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT lupoliang antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT wujiunnjong antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT kowenchien antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT leewensen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani AT hsuehporen antimicrobialactivitiesofceftazidimeavibactamceftolozanetazobactamandotheragentsagainstescherichiacoliklebsiellapneumoniaeandpseudomonasaeruginosaisolatedfromintensivecareunitsintaiwanresultsfromthesurveillanceofmulticenterantimicrobialresistanceintaiwani |